Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 2/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21672110 | 0.95 | MPO (0.39) | MPONLRP3HDAC1HDAC8HDAC6 | |
| SCHEMBL22014769 | 0.89 | MPO (0.36) | MPONLRP3HDAC1HDAC8HDAC6 | |
| SCHEMBL20939390 | 0.77 | MPO (0.38) | MPONLRP3 | |
| SCHEMBL31710359 | 0.77 | MPO (0.38) | MPONLRP3 | |
| SCHEMBL25033609 | 0.74 | CNR2 (0.33) | MPONLRP3HDAC1HDAC8HDAC6 | |
| SCHEMBL21646647 | 0.74 | MPO (0.38) | MPONLRP3HDAC1HDAC8HDAC6 | |
| SCHEMBL23762679 | 0.73 | MPO (0.35) | MPONLRP3 | |
| SCHEMBL22020551 | 0.73 | SMPD3 (0.36) | MPONLRP3 | |
| SCHEMBL23762861 | 0.73 | HDAC1 (0.36) | MPONLRP3HDAC1HDAC8HDAC6 | |
| SCHEMBL22014590 | 0.73 | MPO (0.35) | MPONLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-08 | — | — | US | disclosed |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-23 | — | — | US | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-02 | — | — | US | disclosed |
| US-11560391-B2 | Sulfonylurea compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20230011652-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-12 | — | — | US | disclosed |
| US-20210395268-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210253596-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-11040985-B2 | Chemical compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| WO-2020102096-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS INFLAMMASOME RESEARCH, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230031406-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MPO 13/4885NLRP3 2/4885SSTR4 4564/4885 |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MPO 12/4885NLRP3 2/4885SSTR4 4585/4885 |
| US-20230011652-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MPO 13/4885NLRP3 2/4885SSTR4 4583/4885 |
| US-11718631-B2 | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | MPO 40/4885NLRP3 2/4885SSTR4 4554/4885 |
| US-20210395268-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1B, IL1A, IL18 | MPO 556/4885NLRP3 8/4885SSTR4 2541/4885 |
| US-20230063462-A1 | SULFONIMIDAMIDE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MPO 44/4885NLRP3 2/4885SSTR4 4220/4885 |
| US-11040985-B2 | Chemical compounds as inhibitors of interleukin-1 activity | IL1B, IL1A, IL18 | MPO 556/4885NLRP3 8/4885SSTR4 2541/4885 |
| US-11560391-B2 | Sulfonylurea compounds as inhibitors of interleukin-1 activity | IL1B, IL1A, IL18 | MPO 1206/4885NLRP3 10/4885SSTR4 1807/4885 |
| US-11702428-B2 | Chemical compounds as inhibitors of interleukin-1 activity | IL1B, IL1A, IL18 | MPO 556/4885NLRP3 8/4885SSTR4 2541/4885 |
| US-20230059136-A1 | THE COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MPO 21/4885NLRP3 2/4885SSTR4 4419/4885 |
| US-20210253596-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1A, IL18, IL1B | MPO 209/4885NLRP3 7/4885SSTR4 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.